CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER: NDA 20-671/S-004

CHEMISTRY REVIEW(S)

CHEMIST'S REVIEW

1. ORGANIZATION	2. NDA NUMBER
HFD-150 DODP	20-671

3. NAME AND ADDRESS OF APPLICANT *(City and State)*

SmithKline Beecham Pharmaceuticals
1250 S. Collegeville Road
P.O. Box 5089, Mail Code UP4330
Collegeville, PA 19426-0989
Attention: Richard Swanson
Associate Director, U.S. Regulatory Affairs
Telephone: (610)-917-5769

4. AF NUMBER

5. SUPPLEMENT (S)
NUMBER(S) DATES(S)

6. NAME OF DRUG	7. NONPROPRIETARY NAME		
Hycamtin™	topotecan HCl	SE1-004	23-Dec-97

8. SUPPLEMENT PROVIDES FOR:
a claim of categorical exclusion for an Environmental Assessment to support the treatment of small lung cell cancer

9. AMENDMENTS DATES
BC , 9-Jul-98

10. PHARMACOLOGICAL CATEGORY	11. HOW DISPENSED	12. RELATED IND/NDA/DMF
antineoplastic	RX X OTC ____	

13. DOSAGE FORM(S)	14. POTENCY
lyophilized powder for injection	4 mg

15. CHEMICAL NAME AND STRUCTURE
(S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]-indolizino[1,2-b]quinoline-3,14(4H,12H)-dione monohydrochloride

16. RECORDS AND REPORTS
CURRENT YES___NO___
REVIEWED YES___NO___

17. COMMENTS

See page 2

cc:
NDA 20-671
HFD-150/Div. File
HFD-150/RWood
HFD-150/YAHsieh
HFD-150/DCatterson
R/D Init. by: RHW 7-10-98

18. CONCLUSIONS AND RECOMMENDATIONS

It is recommended that the request for a claim of categorical exclusion for an Environmental Assessment should be approved.

19. REVIEWER

NAME	SIGNATURE	DATE COMPLETED
Yung-Ao Hsieh, Ph.D.	/S/	10-Jul-98

DISTRIBUTION ORIGINAL JACKET x DIVISION FILE x REVIEWER x CSO x SUP. CHEMIST x

Summary of the Application

Hycamtin™ (topotecan hydrochloride) is currently approved in the US as a second-line therapy of patients with metastatic carcinoma of the ovary. Supplemental new drug application SE1-004 provides for the use of Hycamtin™ in the treatment of patients with small cell lung cancer sensitive disease after failure of first-line chemotherapy. In support of this efficacy supplement, SmithKline Beecham (SKB) submitted a claim of categorical exclusion in an amendment, dated July 9, 1998.

SKB reported that the expected level of topotecan introduced into the environment, as the result of the approval of this efficacy supplemental application and the previous approval, will not exceed a concentration of 1 ppb at the point of entry into the aquatic environment. The applicant stated that to his knowledge, no extraordinary circumstances exist.

Conclusion and recommendation

Adequate information has been presented to show that the requested approval of the efficacy supplement NDA 20-671 SE1-004 qualifies for a categorical exclusion from the requirement to prepare an EA under 21 CFR 25.31(b). It is recommended that the claim for a categorical exclusion for an EA should be approved.

/S/

Yung-Ao Hsieh, Ph.D.
Review Chemist, HFD-150

/S/ 7-10-98

Rebecca H. Wood, Ph.D.
Chemistry Team Leader, HFD-150

cc:
NDA 20-671
HFD-150/Div. File
HFD-150/RHWood
HFD-150/YAHsieh
HFD-150/DCatterson